Obesity refers to the increase in body mass due to the increase in the volume of fat and (or) the number of fat cells, or the abnormal increase in the percentage of body fat in body mass, and excessive fat deposition in some parts. Obesity is a potential risk factor for diabetes, cardiovascular disease and other metabolic diseases and tumors. At the same time, in the past 20 years, the prevalence of obesity in China has gradually increased, and obesity has appeared at a younger age, seriously endangering the health of our people. The pathogenesis of obesity is complex. More and more clinical and basic research evidences suggest that obesity is a chronic inflammation and is related to oxidative stress.

Exenatide is a glucagon like peptide 1 (GLP-1) receptor agonist. In the treatment of patients with type 2 diabetes, GLP-1 receptor agonists can control blood sugar and reduce the body mass of patients at the same time. Anti inflammation and anti-oxidation are important mechanisms for GLP-1 receptor agonists to play a therapeutic role. Similar to other GLP-1 receptor agonists, exenatide impurities may have anti-inflammatory and antioxidant effects in many studies in cardiovascular system, nervous system and other fields. It can be seen that the pathogenesis of obesity involves inflammation and oxidative stress mechanisms, and exenatide has weight loss, anti-inflammatory and antioxidant functions. However, the current research on exenatide in the treatment of obesity is limited, and its anti-inflammatory and antioxidant mechanisms have not been clarified. Therefore, this study intends to explore the specific mechanisms of exenatide in treating obesity through anti inflammation and anti-oxidation and the relationship between these mechanisms.

Exenatide is a GLP-1 receptor agonist, which is mainly used in the treatment of type 2 diabetes. In addition to regulating blood glucose and insulin function, it can also reduce the body mass of patients. Basic research shows that exenatide may also have anti-inflammatory and antioxidant effects. Therefore, it is speculated from the mechanism that exenatide may be effective for obese patients who are also involved in inflammation and oxidation in the pathogenesis. In this study, we successfully established a diet induced obesity model in mice, which showed obesity, abnormal glucose metabolism, abnormal insulin action, and inflammation and oxidative stress activation. Compared with the model group mice, the treatment group mice with exenatide intervention had reduced food intake, increased IRS 1 phosphorylation ratio, and its oxidative stress marker HIF-1 α The results suggest that exenatide plays a role in reducing weight and regulating semaglutide api glucose metabolism through anti inflammation and anti-oxidation, thus treating obesity

It is noteworthy that there is also a certain correlation between inflammation and oxidative stress indicators in this study. Studies have shown that inflammation and oxidative stress are interrelated in adipose tissue. For example, the intermittent hypoxia and fmoc-osu oxidative stress in patients with obstructive sleep apnea syndrome, which is also related to insulin resistance, can cause adipose tissue inflammation and further induce insulin resistance, and correcting this hypoxia and oxidative stress can reduce the inflammatory status of patients.